Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

NATICK, Mass., Oct. 28, 2013 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will highlight the strength of its advanced portfolio and plans for delivering additional meaningful innovation to clinicians and patients through a robust schedule of sponsored research presentations at the 25^th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, October 27 – November 2 in San Francisco. 

The clinical presentations will provide new insights into Boston Scientific research and therapy advances in coronary and peripheral artery disease, including aortic valve disease, coronary artery disease and hypertension.

"The industry-leading technologies we will be discussing at TCT showcase our commitment to bringing value-driven solutions that improve outcomes, enhance the patient experience and lower healthcare costs," said Keith Dawkins, M.D., chief medical officer, Boston Scientific. "These technologies are the result of world-wide physician collaboration that underscores our commitment to advancing cardiology together."

Schedule of Events
All programs are Pacific Time, with events held at the Moscone Center unless otherwise indicated.

Monday, October 28

• REDUCE-HTN Clinical Study Interim Six-Month Data: 
  • Professor Horst Sievert, M.D., Ph.D. - Presentation of interim six-month and one-year results from the REDUCE-HTN trial, evaluating renal denervation with the Vessix™ Renal Denervation System, a bipolar radiofrequency balloon catheter, in patients with resistant hypertension 
  • Data to be presented as Featured Clinical Research
  • 6 p.m., Moscone West, 3rd Floor, Room 3000
    
    
• LOTUS™ TAVR System (TF):
  • Ian T. Meredith, A.M., M.B.B.S., Ph.D -- Technology review and summary of data from the REPRISE I and II trials with the Lotus Valve System. Ted E. Feldman, M.D., will follow with case examples.  The Lotus Valve System is the first transcatheter aortic valve replacement (TAVR) device of its kind with an Adaptive Seal™ designed to minimize aortic regurgitation (leaking) around the valve, a proven predictor of mortality, and is both fully repositionable and retrievable prior to release. 
  • Presentations will be featured at the New TAVR Systems II Session on Newcomers with Significant Clinical Data
  • 3:30 p.m., Moscone West, 2^nd Floor, Room 2001.   

Tuesday, October 29

• Advancing Science For Life Satellite Symposium:
  • Special satellite symposium sponsored by Boston Scientific focused on harnessing the power of meaningful innovation
  • Event to feature Mike Mahoney, president and CEO, Boston Scientific, Michael Lewis, journalist and best-selling author of Moneyball and Dean Kamen, science and technology advocate and inventor of the Segway.
  • 7 p.m., Moscone West, 3rd Floor.
    
    
• Need for Permanent Pacemaker Following Implantation of the Repositionable Second-Generation LOTUS Device for the Transcatheter Aortic Valve Replacement:  Results from the Pivotal REPRISE II Trial: 
  • Nicolas Dumonteil, M.D., to discuss results from the REPRISE II Trial, evaluating predictors of the need for a permanent pacemaker following implantation of the repositionable Lotus Valve System for transcatheter aortic valve replacement. 
  • 2:44 p.m., Moscone West, 2^nd Floor, Room 2008.
    
    
• WATCHMAN™ LAAC Long Term Rates by CHADS2 Score: 
  • Saibal Kar, M.D., will present long term event rates of left atrial appendage closure with the WATCHMAN device stratified by the CHADS2 score. 
  • 1 p.m., Moscone West, 3rd Floor, Room 3014.
    
    
• Cost Benefit of WATCHMAN LAAC versus Warfarin – U.S. analysis: 
  • Vivek Reddy, M.D., will present a cost benefit analysis of left atrial appendage closure with the WATCHMAN device versus Warfarin for stroke risk reduction in patients with atrial fibrillation. 
  • 1:13 p.m., Moscone West, 3rd Floor, Room 3014.
    
    
• PLATINUM SV/LL:
  • Paul Teirstein, M.D., will present three-year results from the PLATINUM Small Vessel and Long Lesion Trial evaluating the PROMUS Element™ Stent Platinum Chromium Everolimus-Eluting stent. 
  • Poster session from 3:30 p.m. to 5:30 p.m., Moscone West, 1^st Floor.
    
    
• SuperNOVA Design and Demographics:  Richard Powell, M.D. will present in poster format the design and demographics of the SuperNOVA trial, evaluating the Innova™ Self-Expanding Bare Metal Stent System for stenting of the superficial femoral and proximal popliteal arteries. 
  • Poster session from 3:30 p.m. to 5:30 p.m., Exhibit Hall, Moscone West, 1^st Floor.
    
    
• TE-PROVE Primary Endpoint: 
  • Corrado Tamburino, M.D., will present primary endpoint results from the TAXUS® Element™ Post-Approval Surveillance Study (TE-PROVE): One-Year Outcomes in Unselected Patients Treated with a Thin-Strut, Platinum-Chromium, Paclitaxel-Eluting Stent.
  • Poster session from 3:30 p.m. to 5:30 p.m., Exhibit Hall, Moscone West, 1^st Floor.
    
    
• ION™ U.S. PAS Primary Endpoint: 
  • Louis Cannon, M.D., will present One-Year "Real-World" Outcomes Following Implantation of the ION Paclitaxel-Eluting Platinum Chromium Coronary Stent System in Routine Clinical Practice:  Primary Endpoint Results of the ION U.S. Post-Approval Registry. 
  • Poster session from 3:30 p.m. to 5:30 p.m., Exhibit Hall, Moscone West, 1^st Floor.
    
    
• Preclinical Ovine TAVR Model:  Jeannot Potvin, M.D., will present an evaluation of transcatheter orthotopic aortic valve implantation in sheep: chronic survival and valve performance. 
  • Recognized as one of the Top 50 posters at TCT 2013
  • 3:30 p.m. to 5:30 p.m., Exhibit Hall, Moscone West, 1^st Floor.
    
    
• Preclinical WATCHMAN/ACP Canine Model: 
  • Dongming Hou, M.D., Ph.D., will present the Anatomical Effects on the Left Atrium After Percutaneous LAA Closure with the WATCHMAN vs. Amplatzer™ Cardiac Plug in a Canine Model. 
  • Recognized as one of the Top 50 posters at TCT 2013
  • 3:30 p.m. to 5:30 p.m., Exhibit Hall, Moscone West, 1^st Floor.

Thursday, October 31

• REPRISE II Primary Endpoint: 
  • Ian Meredith, A.M., M.B.B.S., Ph.D., will present primary endpoint results of the 120-patient REPRISE II study, evaluating transcatheter aortic valve replacement for severe symptomatic aortic stenosis using the repositionable Lotus Valve System. 
  • Presented as First Report Investigations at 2:28 p.m., Moscone North, Lower Level, Hall D, Coronary.  

Conference attendees and media are invited to visit the Boston Scientific "Advancing Cardiology Together" exhibit at booth 1817 in the Main Exhibit Hall.  Media attending TCT can also arrange to tour the Boston Scientific Technology Suite on Wednesday, October 30 from 4 p.m. to 5 p.m., South Hall, Suites 30-31.

The Lotus, Vessix, WATCHMAN and Innova devices are investigational devices and not available for sale in the U.S.

About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.  As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our business plans, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements. 

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

CONTACT:  
Ryan Davenport
763-494-2664 (office)
Global Media Relations
Boston Scientific Corporation
[email protected]

Michael Campbell
508-650-8023 (office)
Investor Relations
Boston Scientific Corporation
[email protected]

SOURCE Boston Scientific Corporation